Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation

Annals of the Rheumatic Diseases

Volumn 61, Issue 4, 2002, Pages 311-318

  den Broeder, A A ^a   Joosten, L A B ^a   Saxne, T ^b   Heinegard D ^b   Fenner, H ^c   Miltenburg, A M M ^d   Frasa, W L H ^d   van Tits, L J ^a   Buurman, W A ^e   van Riel, P L C M ^a   van de Putte, L B A ^a   Barrera, P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Organon ^*

^d NV ORGANON   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLOPHOSPHAMIDE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLYCOPROTEIN GP 39; GOLD SALT; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARTILAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; ENDOTHELIUM; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; JOINT RADIOGRAPHY; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SYNOVIUM; TURNOVER TIME;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE; CELL ADHESION MOLECULES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036201985     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.4.311     Document Type: Article

References (46)

1. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
2. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
3. Generation of fully human anti-TNF antibody D2E7
4. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti TNF antibody D2E7 in patients with rheumatoid arthritis. Results of a phase I study
5. Long term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
6. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
7. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7
8. Effective combination of the fully human anti-TNF antibody D2E7 and methotrexate in active rheumatoid arthritis
9. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
10. Effect of a fully human anti-TNF alpha antibody on the local and systemic expression of TNFalpha and IL-1 beta
11. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
12. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
13. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
14. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-alpha (cA2) therapy
15. Serum YKL-40, a chondrocyte derived protein, is reduced by infliximab (anti-TNF) therapy in patients with rheumatoid arthritis
16. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
17. Infliximab and methotrexate in the treatment of rheumatoid arthritis
18. Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
19. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint disease
20. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
21. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
22. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
23. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials
24. Smallest detectable difference in radiological progression
25. The course of radiologic damage during the first six years of rheumatoid arthritis
26. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism
27. Cartilage oligomeric matrix protein: A novel marker of cartilage turnover detectable in synovial fluid and blood
28. Increased serum proMMP-3 in inflammatory arthritides: A potential indicator of synovial inflammatory monokine activity
29. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro
30. Analysis of soluble adhesion molecules
31. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the first three years of the disease
32. How to read radiographs according to the Sharp/van der Heijde method
33. Methodological issues in radiographic scoring methods in rheumatoid arthritis
34. Imaging in rheumatoid arthritis: Results of group discussions
35. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions
36. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid other surrogate markers
37. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis
38. Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: Relationship to development of joint destruction in hands and feet
39. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis
40. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
41. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression
42. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis
43. Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis
44. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis
45. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis
46. Serum MMP-3 in rheumatoid arthritis: Correlation with systemic inflammation but not with erosive status